Cerity Partners LLC bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 11,640 shares of the company’s stock, valued at approximately $92,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of PTGX. Los Angeles Capital Management LLC acquired a new position in shares of Protagonist Therapeutics in the second quarter valued at approximately $561,000. Fairmount Funds Management LLC acquired a new position in shares of Protagonist Therapeutics in the first quarter worth $13,024,000. Dupont Capital Management Corp purchased a new stake in shares of Protagonist Therapeutics during the second quarter worth $131,000. Franklin Street Advisors Inc. NC raised its stake in shares of Protagonist Therapeutics by 90.0% in the second quarter. Franklin Street Advisors Inc. NC now owns 42,220 shares of the company’s stock valued at $334,000 after acquiring an additional 20,000 shares in the last quarter. Finally, RTW Investments LP boosted its holdings in Protagonist Therapeutics by 84.4% in the first quarter. RTW Investments LP now owns 4,794,499 shares of the company’s stock valued at $113,534,000 after purchasing an additional 2,194,677 shares during the period.
Protagonist Therapeutics Stock Performance
Shares of NASDAQ PTGX opened at $7.60 on Thursday. The stock’s 50-day simple moving average is $8.22 and its 200-day simple moving average is $8.79. The firm has a market capitalization of $373.90 million, a PE ratio of -2.84 and a beta of 2.35. Protagonist Therapeutics, Inc. has a fifty-two week low of $6.91 and a fifty-two week high of $37.04.
Wall Street Analysts Forecast Growth
PTGX has been the topic of several recent research reports. JMP Securities assumed coverage on Protagonist Therapeutics in a report on Thursday, August 25th. They set an “outperform” rating and a $21.00 price target on the stock. BTIG Research reduced their target price on shares of Protagonist Therapeutics to $41.00 in a report on Wednesday, November 16th. HC Wainwright lowered their price target on shares of Protagonist Therapeutics from $50.00 to $33.00 and set a “buy” rating for the company in a report on Thursday, November 10th. Finally, StockNews.com assumed coverage on shares of Protagonist Therapeutics in a report on Wednesday, October 12th. They issued a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc, a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.
- Get a free copy of the StockNews.com research report on Protagonist Therapeutics (PTGX)
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.